Onconetix Statistics
Total Valuation
Onconetix has a market cap or net worth of $87,308. The enterprise value is -$3.33 million.
Important Dates
The last earnings date was Wednesday, May 13, 2026, before market open.
| Earnings Date | May 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Onconetix has 69,292 shares outstanding.
| Current Share Class | 69,292 |
| Shares Outstanding | 69,292 |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +1,903.66% |
| Owned by Insiders (%) | 0.51% |
| Owned by Institutions (%) | 2.41% |
| Float | 63,201 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.13 |
| Forward PS | n/a |
| PB Ratio | 0.29 |
| P/TBV Ratio | 0.06 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.41, with a Debt / Equity ratio of 0.02.
| Current Ratio | 1.41 |
| Quick Ratio | 1.23 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -12.81 |
Financial Efficiency
Return on equity (ROE) is -123.28% and return on invested capital (ROIC) is -33.82%.
| Return on Equity (ROE) | -123.28% |
| Return on Assets (ROA) | -25.23% |
| Return on Invested Capital (ROIC) | -33.82% |
| Return on Capital Employed (ROCE) | -57.65% |
| Weighted Average Cost of Capital (WACC) | 113.59% |
| Revenue Per Employee | $367,599 |
| Profits Per Employee | -$5.01M |
| Employee Count | 2 |
| Asset Turnover | 0.04 |
| Inventory Turnover | 1.02 |
Taxes
In the past 12 months, Onconetix has paid $525 in taxes.
| Income Tax | 525 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -99.55% in the last 52 weeks. The beta is 3.01, so Onconetix's price volatility has been higher than the market average.
| Beta (5Y) | 3.01 |
| 52-Week Price Change | -99.55% |
| 50-Day Moving Average | 11.26 |
| 200-Day Moving Average | 88.84 |
| Relative Strength Index (RSI) | 24.53 |
| Average Volume (20 Days) | 1,284,283 |
Short Selling Information
| Short Interest | 522,813 |
| Short Previous Month | 228,855 |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.03 |
Income Statement
In the last 12 months, Onconetix had revenue of $735,198 and -$10.03 million in losses. Loss per share was -$30.04.
| Revenue | 735,198 |
| Gross Profit | 585,426 |
| Operating Income | -6.78M |
| Pretax Income | -9.70M |
| Net Income | -10.03M |
| EBITDA | -6.77M |
| EBIT | -6.78M |
| Loss Per Share | -$30.04 |
Full Income StatementBalance Sheet
The company has $3.72 million in cash and $289,922 in debt, with a net cash position of $3.43 million or $49.45 per share.
| Cash & Cash Equivalents | 3.72M |
| Total Debt | 289,922 |
| Net Cash | 3.43M |
| Net Cash Per Share | $49.45 |
| Equity (Book Value) | 11.75M |
| Book Value Per Share | 4.26 |
| Working Capital | 1.26M |
Full Balance SheetCash Flow
| Operating Cash Flow | -9.80M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 15,820 |
| Net Borrowing | -4.69M |
| Free Cash Flow | -9.80M |
| FCF Per Share | -$141.43 |
Full Cash Flow StatementMargins
| Gross Margin | 79.63% |
| Operating Margin | -922.72% |
| Pretax Margin | -1,319.48% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
